Tofflon(SZ:300171)2025-01-24 08:24Financial Performance Forecast - The estimated net profit for 2024 is projected to be between RMB 185 million and RMB 235 million, representing a decline of 60.85% to 69.18% compared to the previous year[3] - The estimated net profit after deducting non-recurring gains and losses is projected to be between RMB 105 million and RMB 155 million, reflecting a decrease of 72.17% to 81.15% year-on-year[3] - The impact of non-recurring gains and losses on the company's net profit is estimated to be around RMB 80 million[6] - The performance forecast period is from January 1, 2024, to December 31, 2024[3] Market Conditions and Competition - The decline in performance is primarily attributed to a slowdown in fixed asset investment in the domestic biopharmaceutical industry, leading to a temporary decrease in demand for pharmaceutical equipment[5] - Increased competition in the pharmaceutical equipment industry is driven by pharmaceutical companies tightening control over R&D and capacity construction costs[5] - The company is adjusting its product market competition strategy to enhance penetration into quality customer segments and stabilize market share[5] Financial Reporting and Caution - The comprehensive gross profit margin is expected to decline compared to the same period last year due to the aforementioned factors[5] - The financial data presented is preliminary and has not been audited by the accounting firm[4] - Detailed financial data will be disclosed in the 2024 annual report, and investors are advised to be cautious and make informed decisions[7]